SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 12)*

XOMA Royalty Corp

(Name of Issuer)

Common Stock, \$0.0075 par value

(Title of Class of Securities)

98419J206

(CUSIP Number)

JAMES KRATKY BVF PARTNERS L.P., 44 Montgomery St., 40th Floor San Francisco, CA, 94104 415-525-8830

KENNETH A. SCHLESINGER, ESQ.
OLSHAN FROME WOLOSKY LLP, 1325 Avenue of the Americas
New York, NY, 10019
212-451-2300

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

05/16/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

4	Name of reporting person
'	BIOTECHNOLOGY VALUE FUND L P
	Check the appropriate box if a member of a Group (See Instructions)
2	✓ (a)□ (b)

3	SEC use only		
4	Source of funds (See Instructions) WC		
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)		
6	Citizenship or place of organization DELAWARE		
	7	Sole Voting Power 0.00	
Number of Shares Benefici	8	Shared Voting Power 1,322,758.00	
ally Owned by Each Reporti	9	Sole Dispositive Power 0.00	
ng Person With:	10	Shared Dispositive Power 1,322,758.00	
11	Aggregate amount beneficially owned by each reporting person 1,322,758.00		
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
13	Percent of class represented by amount in Row (11) 11.1 %		
14	Type of R	Reporting Person (See Instructions)	

1	Name of reporting person		
	BVF I GP LLC		
	Check the appropriate box if a member of a Group (See Instructions)		
2	✓ (a)□ (b)		
3	SEC use only		
4	Source of funds (See Instructions)		
4	AF		
_	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)		
5			
6	Citizenship or place of organization		
6	DELAWARE		

		Г	
Number of Shares Benefici ally Owned by Each Reporti	7	Sole Voting Power	
	,	0.00	
	8	Shared Voting Power	
		1,322,758.00	
	9	Sole Dispositive Power	
ng Person	9	0.00	
With:	10	Shared Dispositive Power	
	10	1,322,758.00	
11	Aggregate amount beneficially owned by each reporting person		
11	1,322,758.00		
40	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
12			
42	Percent of class represented by amount in Row (11)		
13	11.1 %		
	Type of Reporting Person (See Instructions)		
14	00		

CUSIP No.

1	Name of r	eporting person		
'	BIOTECHNOLOGY VALUE FUND II LP			
2	Check the appropriate box if a member of a Group (See Instructions)			
	(b)			
3	SEC use only			
4	Source of funds (See Instructions)			
1 7	wc			
_	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)			
5				
_	Citizenship or place of organization			
6	DELAWARE			
	7	Sole Voting Power		
Number		0.00		
of Shares Benefici	8	Shared Voting Power		
ally Owned		1,267,545.00		
by Each Reporti		Sole Dispositive Power		
ng Person	9	0.00		
With:	40	Shared Dispositive Power		
	10	1,267,545.00		

11	Aggregate amount beneficially owned by each reporting person
	1,267,545.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	
42	Percent of class represented by amount in Row (11)
13	10.6 %
	Type of Reporting Person (See Instructions)
14	PN
1	

_				
1	Name of reporting person			
	BVF II GP LLC			
	Check the appropriate box if a member of a Group (See Instructions)			
2	☑ (a)			
	(b)			
3	SEC use	only		
4	Source of	funds (See Instructions)		
4	AF			
	Check if o	lisclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)		
5				
	Citizensh	ip or place of organization		
6	DELAWARE			
		Sole Voting Power		
	7	0.00		
Number of		Shared Voting Power		
Shares Benefici	8			
ally Owned		1,267,545.00		
by Each Reporti	9	Sole Dispositive Power		
ng Person		0.00		
With:	10	Shared Dispositive Power		
		1,267,545.00		
44	Aggregate amount beneficially owned by each reporting person			
11	1,267,545.00			
40	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)			
12				
45	Percent of class represented by amount in Row (11)			
13	10.6 %			
	Type of R	eporting Person (See Instructions)		
14	00			

CUSIP No. 98419J206

1	Name of reporting person		
	Biotechnology Value Trading Fund OS LP		
	Check the appropriate box if a member of a Group (See Instructions)		
2	✓ (a)✓ (b)		
3	SEC use	only	
4	Source of funds (See Instructions)		
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)		
6	Citizenship or place of organization CAYMAN ISLANDS		
Number	7	Sole Voting Power	
of Shares		Shared Voting Power	
Benefici ally Owned	8	0.00	
by Each Reporti	9	Sole Dispositive Power	
ng Person		0.00	
With:	10	Shared Dispositive Power	
		0.00	
11	Aggregate amount beneficially owned by each reporting person 0.00		
40	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
12			
13	Percent of class represented by amount in Row (11)		
13	0 %		
14	Type of R	eporting Person (See Instructions)	
14	PN		

SCHEDULE 13D

|--|--|

1	Name of reporting person				
	BVF Partners OS Ltd.				

	Check the appropriate box if a member of a Group (See Instructions)		
2	✓ (a)✓ (b)		
3	SEC use	only	
4	Source of funds (See Instructions)		
7	00		
5	Check if	disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
6	Citizensh	ip or place of organization	
	CAYMAN ISLANDS		
	7	Sole Voting Power	
Number	,	0.00	
of Shares	8	Shared Voting Power	
Benefici ally Owned		0.00	
by Each Reporti	9	Sole Dispositive Power	
ng Person		0.00	
With:	10	Shared Dispositive Power	
		0.00	
	Aggregate amount beneficially owned by each reporting person		
11	0.00		
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
12			
13	Percent of class represented by amount in Row (11)		
13	0 %		
14	Type of R	Reporting Person (See Instructions)	
17	со		

alloin II	00440 1000
CUSIP No.	98419J206

1	Name of reporting person
	BVF GP HOLDINGS LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	✓ (a)□ (b)
3	SEC use only
4	Source of funds (See Instructions)
	AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6	Citizenship or place of organization		
	DELAWARE		
	7	Sole Voting Power	
Number		0.00	
of Shares	8	Shared Voting Power	
Benefici ally Owned	•	2,590,303.00	
by Each Reporti	9	Sole Dispositive Power	
ng Person		0.00	
With:	10	Shared Dispositive Power	
	10	2,590,303.00	
	Aggregate amount beneficially owned by each reporting person		
11	2,590,303.00		
42	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)		
12			
13	Percent of class represented by amount in Row (11)		
13	21.6 %		
14	Type of Reporting Person (See Instructions)		
1-7	00		

1	Name of reporting person
	BVF PARTNERS L P/IL
2	Check the appropriate box if a member of a Group (See Instructions)
	✓ (a)✓ (b)
3	SEC use only
4	Source of funds (See Instructions)
4	AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
3	
6	Citizenship or place of organization
0	DELAWARE

Number of Shares	7	Sole Voting Power
		0.00
	8	Shared Voting Power
Benefici ally Owned		2,590,303.00
by Each Reporti	9	Sole Dispositive Power
ng Person		0.00
With:	10	Shared Dispositive Power
	10	2,590,303.00
44	Aggregate amount beneficially owned by each reporting person	
11	2,590,303.00	
40	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
12		
40	Percent of class represented by amount in Row (11)	
13	21.6 %	
14	Type of Reporting Person (See Instructions)	
14	IA, PN	

1	Name of reporting person BVF INC/IL		
2	Check the appropriate box if a member of a Group (See Instructions) (a) (b)		
3	SEC use only		
4	Source of funds (See Instructions) AF		
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)		
6	Citizenship or place of organization DELAWARE		
l			
İ			

Number of Shares Benefici ally	7	Sole Voting Power
		0.00
	8	Shared Voting Power
		2,590,303.00
Owned by Each	9	Sole Dispositive Power
Reporti ng		0.00
Person With:		Shared Dispositive Power
	10	2,590,303.00
11	Aggregate amount beneficially owned by each reporting person	
	2,590,303.00	
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
12		
40	Percent of class represented by amount in Row (11)	
13	21.6 %	
	Type of Reporting Person (See Instructions)	
14	со	

1	Name of reporting person	
	LAMPERT MARK N	
	Check the appropriate box if a member of a Group (See Instructions)	
2	✓ (a)□ (b)	
3	SEC use only	
	Source of funds (See Instructions)	
4	AF	
_	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
5		
	Citizenship or place of organization	
6	UNITED STATES	

Number of Shares Benefici ally	7	Sole Voting Power
		0.00
	8	Shared Voting Power
		2,590,303.00
Owned by Each Reporti	9	Sole Dispositive Power
ng Person		0.00
With:	40	Shared Dispositive Power
	10	2,590,303.00
	Aggregate amount beneficially owned by each reporting person	
11	2,590,303.00	
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)	
12		
40	Percent of class represented by amount in Row (11)	
13	21.6 %	
44	Type of Reporting Person (See Instructions)	
14	IN	

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock, \$0.0075 par value

(b) Name of Issuer:

XOMA Royalty Corp

(c) Address of Issuer's Principal Executive Offices:

2200 POWELL STREET, SUITE 310, EMERYVILLE, CALIFORNIA, 94608.

Item 3. Source and Amount of Funds or Other Consideration

Item 3 is hereby amended and restated to read as follows:

The Shares purchased by BVF and BVF2 were purchased with working capital (which may, at any given time, include margin loan s made by brokerage firms in the ordinary course of business) in open market transactions, except as otherwise noted. The aggre gate purchase price of the 1,322,758 Shares owned directly by BVF is approximately \$11,151,698, including brokerage commissions. The aggregate purchase price of the 1,267,545 Shares owned directly by BVF2 is approximately \$12,811,805, including broker age commissions.

The aggregate purchase price of the 2,313 shares of Series X Preferred Stock owned directly by BVF is approximately \$9,321,390 , including brokerage commissions. The aggregate purchase price of the 1,506 shares of Series X Preferred Stock owned directly by BVF2 is approximately \$6,069,180, including brokerage commissions. The aggregate purchase price of the 412 shares of Serie s X Preferred Stock owned directly by Trading Fund OS is approximately \$1,660,360, including brokerage commissions. The aggregate purchase price of the 772 shares of Series X Preferred Stock held in the Partners Managed Accounts is approximately \$3,11,160, including brokerage commissions.

Item 5. Interest in Securities of the Issuer

(a) Item 5(a) is hereby amended and restated to read as follows:

The aggregate percentage of Shares reported owned by each person named herein is based on 11,966,889 Shares outstanding a s of May 8, 2025, which is the total number of Shares outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 13, 2025.

As of the date hereof, the Reporting Persons and the Partners Managed Accounts hold an aggregate of 5,003 shares of Series X Preferred Stock, convertible into an aggregate of 5,003,000 Shares. Each share of Series X Preferred Stock is convertible into 1,0 00 Shares. The Reporting Persons and the Partners Managed Accounts do not have the right to convert any portion of the Series X Preferred Stock held by them to the extent that, after giving effect to such conversion, they, together with their Attribution Parties (as defined in the Series X Preferred Stock Certificate of Designation of Preferences, Rights and Limitations), would beneficially o wn a number of Shares in excess of 19.99% of the number of Shares outstanding immediately after giving effect to the issuance of Shares pursuant to such conversion (the "Series X Beneficial Ownership Limitation"). As of the date hereof, the Series X Beneficia I Ownership Limitation prohibits the conversion of all the Series X Preferred Stock held by the Reporting Persons and the Partners Managed Accounts.

As of the date hereof, (i) BVF beneficially owned 1,322,758 Shares, excluding 2,313,000 Shares issuable upon the conversion of c ertain Series X Preferred Stock held by it, representing percentage ownership of approximately 11.1% of the Shares outstanding, (ii) BVF2 beneficially owned 1,267,545 Shares, excluding 1,506,000 Shares issuable upon the conversion of certain Series X Preferred Stock held by it, representing percentage ownership of approximately 10.6% of the Shares outstanding, (iii) Trading Fund O S beneficially owned 0 Shares, excluding 412,000 Shares issuable upon the conversion of certain Series X Preferred Stock held by it, representing percentage ownership of 0% of the Shares outstanding, and (iv) 0 Shares were held in the Partners Managed Accounts, excluding 772,000 Shares issuable upon the conversion of certain Series X Preferred Stock held in the Partners Managed Accounts, representing percentage ownership of 0% of the Shares outstanding.

BVF GP, as the general partner of BVF, may be deemed to beneficially own the 1,322,758 Shares beneficially owned by BVF, representing percentage ownership of approximately 11.1% of the Shares outstanding.

BVF2 GP, as the general partner of BVF2, may be deemed to beneficially own the 1,267,545 Shares beneficially owned by BVF2, representing percentage ownership of approximately 10.6% of the Shares outstanding.

Partners OS, as the general partner of Trading Fund OS, may be deemed to beneficially own 0 Shares, representing percentage o wnership of 0% of the Shares outstanding.

BVF GPH, as the sole member of each of BVF GP and BVF2 GP, may be deemed to beneficially own the 2,590,303 Shares beneficially owned in the aggregate by BVF and BVF2, representing percentage ownership of approximately 21.6% of the Shares outst anding.

Partners, as the investment manager of BVF and BVF2, may be deemed to beneficially own the 2,590,303 Shares beneficially own ned in the aggregate by BVF and BVF2, representing percentage ownership of approximately 21.6% of the Shares outstanding.

BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 2,590,303 Shares beneficially owned by Part ners, representing percentage ownership of approximately 21.6% of the Shares outstanding.

Mr. Lampert, as a director and officer of BVF Inc. may be deemed to beneficially own the 2,590,303 Shares beneficially owned by BVF Inc., representing percentage ownership of approximately 21.6% of the Shares outstanding.

(c) Item 5(c) is hereby amended to add the following:

On May 16, 2025, the Reporting Persons sold an aggregate of 392,723 Shares for a price of \$27.10 per Share in a private transaction as follows: 127,407 Shares sold by BVF and 265,316 Shares sold by BVF2. There were no other transactions by the Reporting Persons in the securities of the Issuer during the past sixty days.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BIOTECHNOLOGY VALUE FUND L P

Signature: /s/ Mark N. Lampert

Name/Title: Mark N. Lampert, Authorized Signatory

Date: 05/20/2025

BVF I GP LLC

Signature: /s/ Mark N. Lampert

Name/Title: Mark N. Lampert, Authorized Signatory

Date: 05/20/2025

BIOTECHNOLOGY VALUE FUND II LP

Signature: /s/ Mark N. Lampert

Name/Title: Mark N. Lampert, Authorized Signatory

Date: 05/20/2025

BVF II GP LLC

Signature: /s/ Mark N. Lampert

Name/Title: Mark N. Lampert, Authorized Signatory

Date: 05/20/2025

Biotechnology Value Trading Fund OS LP

Signature: /s/ Mark N. Lampert

Name/Title: Mark N. Lampert, Authorized Signatory

Date: 05/20/2025

BVF Partners OS Ltd.

Signature: /s/ Mark N. Lampert

Name/Title: Mark N. Lampert, Authorized Signatory

Date: 05/20/2025

BVF GP HOLDINGS LLC

Signature: /s/ Mark N. Lampert

Name/Title: Mark N. Lampert, Authorized Signatory

Date: 05/20/2025

BVF PARTNERS L P/IL

Signature: /s/ Mark N. Lampert

Name/Title: Mark N. Lampert, Authorized Signatory

Date: 05/20/2025

BVF INC/IL

Signature: /s/ Mark N. Lampert

Name/Title: Mark N. Lampert, Authorized Signatory

Date: 05/20/2025

LAMPERT MARK N

Signature: /s/ Mark N. Lampert
Name/Title: Mark N. Lampert
Date: 05/20/2025